JMP Securities Maintains Market Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $381
JMP Securities Maintains Market Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $381
JMP證券維持Madrigal製藥的市場跑贏大盤,將目標股價下調至381美元
JMP Securities analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Outperform and lowers the price target from $397 to $381.
JMP證券分析師喬納森·沃勒本維持Madrigal Pharmicals(納斯達克股票代碼:MDGL)的市場表現跑贏大盤,並將目標股價從397美元下調至381美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。